Recurrent nationwide shortage of tuberculin skin test antigen solutions : CDC recommendations for patient care and public health practice
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Recurrent nationwide shortage of tuberculin skin test antigen solutions : CDC recommendations for patient care and public health practice

Filetype[PDF-1.58 MB]


  • English
    • Details You May Also Like

    Details:

    • Journal Article:
      HAN
    • Corporate Authors:
      Centers for Disease Control and Prevention (U.S.)
    • Description:
      September 04, 2013, 13:00 ET (1:00 PM ET)

      CDCHAN-00355

      In HAN 345 (http://emergency.cdc.gov/HAN/han00345.asp), April 2013, CDC reported that TUBERSOL®, a product of Sanofi Pasteur Limited, was in shortage nationwide. Although supplies were restored in early June 2013, TUBERSOL® is in shortage again until at least the middle o f October 2013. A t the current time, the 5 tuberculin units/0.1 mL, 5 mL (50 tests), multiple dose vials are unavailable. The 5 tuberculin units/0.1 mL, 1 mL (10 tests), multiple dose vials are in limited supply. This notice updates and supersedes the advice in HAN 345 and advises public health officials, clinicians, and workers in occupational health and infection control about how to adapt testing protocols to the recurrent shortage.

      TUBERSOL® is one o f two purified-protein derivative (PPD) tuberculin antigen solutions that are licensed by the United States Food and Drug Administration (FDA). JHP Pharmaceuticals, LLC, manufactures APLISOL®, the other PPD tuberculin product that is licensed by FDA. JHP Pharmaceuticals, LLC, has notified FDA that APLISOL® is on allocation, meaning that historical customers have precedence for buying the product, and APLISOL® is available in restricted quantity. Regional shortages o f APLISOL® have been reported since healthcare providers switched from TUBERSOL® to APLISOL®.

    • Subjects:
    • Series:
      HAN ; 355
    • Document Type:
      HAN Health Update
    • Place as Subject:
      United States
    • Location:
      North America
    • Collection(s):
    • Main Document Checksum:
    • Download URL:
    • File Type:

    Supporting Files

    • No Additional Files

    More +

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov